ZS Pharma to Present Data from Phase 3 Trial of ZS-9 in Late-Breaking Oral Presentation at National Kidney Foundation’s 2014 Spring Clinical Meetings
April 22, 2014 – COPPELL, Texas–ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that data from a pivotal Phase 3 trial of ZS-9, an investigational treatment for hyperkalemia, will be presented as a late-breaking clinical trial oral presentation at the National Kidney Foundation’s 2014 Spring Clinical Meetings in Las Vegas.
April 3, 2014
A month removed from raising $45 million in venture backing, San Diego’s Lumena Pharmaceuticals wants $75 million more as it plots a Wall Street debut, piling up cash to advance its two liver treatments. Read MoreRead More
RiverVest Venture Partners Promotes Niall O’Donnell to Managing Director; Michael Berman Joins as Venture Partner
ST. LOUIS (April 2, 2014) – RiverVest Venture Partners today announced the promotion of Niall O’Donnell, Ph.D., to Managing Director. The life sciences venture capital firm also announced that medical device entrepreneur Mike Berman, a long-time member of RiverVest’s Scientific & Industry Advisory Board, has joined the firm as Venture Partner.Read More
“The Frank Drebin Approach to Healthcare” by RiverVest’s Niall O’Donnell, appearing in the Rady Business Journal, a Publication of the Rady School of Management. University of California, San Diego. Winter, 2014. Read moreRead More